Aspirin for the prevention of cardio- vascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396 404. 877. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388 391. 878. Hayden M, Pignone M, Phillips C, Mulrow C.Aspirin for the primary pre- vention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161 172. 879. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged anti- platelet therapy in various categories of patients: Antiplatelet Trialists Collaboration. BMJ. 1994;308:81 106. 880. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol. 2000;57:326 332. 881. Robinson JG, Rahilly-Tierney C, Lawler E, Gaziano JM. Benefits associ- ated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. J Clin Lipidol. 2012;6:58 65. 882. Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Uemura S, Kanauchi M, Doi N, Sakuma M, Jinnouchi H, Sugiyama S, Waki M, SaitoY; JPAD Trial Investigators. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure: sub- analysis from the JPAD trial. Circ J. 2012;76:1526 1532. 883. 